Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulongga-4 is a traditional Mongolian medicine (TMM) formula developed by the Inner Mongolia Autonomous Region International Mongolian Medicine Hospital for the treatment of acute infectious diarrhea. The formulation is a combination of four medicinal herbs: *Stellera chamaejasme* L., *Terminalia chebula* Retz., *Zingiber officinale* Rosc., and *Piper longum* L. It is traditionally used to clear heat, detoxify, and harmonize the stomach and intestines. Clinical studies and traditional use indicate that Sulongga-4 possesses potent antibacterial and anti-inflammatory activities, effectively reducing the frequency of bowel movements and alleviating symptoms such as abdominal pain and vomiting associated with intestinal infections. It is currently utilized as a hospital-made preparation in Inner Mongolia, China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sulongga-4.